 Oyster Point Pharma NASDAQ:OYST was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research note issued on Saturday, Zacks.com reports. The brokerage presently has a 29.00 target price on the stock. Zacks Investment Researchs price objective suggests a potential upside of 14.90 from the companys current price. According ... 